AstraZeneca presents results from positive phase III TULIP 2 trial for anifrolumab to treat SLE at ACR meeting

AstraZeneca presents detailed results from the positive phase III TULIP 2 trial for anifrolumab, a potential new medicine for the treatment of moderate to severe systemic lupus erythematosus (SLE), which demonstrated superiority across multiple efficacy endpoints versus placebo, with both arms receiving standard of care.



Geen nieuws missen?
Volg de duizenden farma professionals die via e-mail lezen

Uw inschrijving is gelukt.